Melorheostosis

Melorheostosis (Greek melos, limb; rhein, flow; osteon, bone) is a rare, sporadic sclerosing bone dysplasia of dense cortical hyperostosis, recognised on radiographs by its dripping candle wax appearance. Leri and Joanny first described it in 1922, and fewer than 500 cases have been reported, which makes it one of the rarest bone conditions. The 2018 discovery of somatic MAP2K1 mutations by Kang and colleagues transformed understanding of how it arises.

Who. The estimated incidence is 1 per 1,000,000. It can present at any age, but 50% present before age 20. The sexes are equally affected, although the Mayo Clinic cohort reported a 4:1 female predominance. It is sporadic: the mutation is a somatic mosaic one, not inherited.

Natural history. Onset is insidious, anywhere from childhood to adulthood, and the disease progresses slowly over decades. Pain is the most common symptom; stiffness and contractures also occur. It is benign but disabling, with no malignant transformation.

Where. Disease is usually unilateral and confined to one limb:

• Lower limb - 70% of cases
• Upper limb - 20%
• Axial skeleton - rare (10%), usually in combination with limb disease

Monostotic and polyostotic disease have been quoted as equally common, with polyostotic disease often in adjacent bones; in the Mayo Clinic cohort, two-thirds had polyostotic involvement.

The mutation. Kang and colleagues identified somatic activating mutations in MAP2K1 (mitogen-activated protein kinase kinase 1), the gene encoding MEK1, a dual-specificity kinase, in melorheostosis lesions; the mutation is found in approximately 50% of cases. It is post-zygotic and present in affected tissue only, not blood, which confirms somatic mosaicism and explains both the sporadic, non-inherited nature of the disease and its mosaic distribution.

The pathway. The mutation drives constitutive ERK activation in osteoblasts through the RAS-RAF-MEK-ERK cascade, and the result is osteoblast hyperactivity and excessive bone formation. The mechanism is subtler than too much bone: the Kang study showed that the mutation increases osteoblast proliferation yet inhibits BMP2-mediated mineralisation and differentiation, producing excess unmineralised osteoid rather than simply more normal bone. The consequences reach beyond the osteoblast:

• Bone remodelling - uncoupled, favouring formation
• Soft tissues - fibroblast activation and fibrosis
• Vasculature - vascular malformations in some cases
• Skin - scleroderma-like changes over affected areas

Two genetic routes. The common, sporadic isolated disease is driven by the post-zygotic MAP2K1 (MEK1) mutation, and a minority carry related somatic RAS-MAPK changes (KRAS, SMAD3). The rarer familial route runs through germline loss-of-function LEMD3 (MAN1) mutations, which cause osteopoikilosis and Buschke-Ollendorff syndrome (osteopoikilosis plus connective-tissue naevi); melorheostosis can arise within these families as the osteopoikilosis-associated, or mixed sclerosing bone dysplasia, form. LEMD3 normally antagonises TGF-beta/BMP signalling.

Why the route matters. Isolated sporadic disease is a somatic MAP2K1 problem and carries no inheritance risk. Melorheostosis appearing alongside osteopoikilosis or connective-tissue naevi points to a germline LEMD3 disorder, which is autosomal dominant, and that distinction changes family counselling (the osteopoikilosis topic covers the LEMD3 detail).

The sclerotomal theory. The classic explanation for the distribution is that the disease affects bones, muscles, fascia and skin derived from a single embryonic segment. The sclerotome is described both as the somite derivative that forms a vertebra and its associated bones and as the territory of a single sensory nerve root, which is why the disease runs along one side of a bone in linear, segmental fashion, often confined to one limb, and stops at a segmental boundary rather than obeying vascular or muscular anatomy. The same segment explains why skin and soft-tissue changes overlie the affected bones in a dermatomal pattern.

Where the theory fails. A post-zygotic mutation affecting a single cell lineage fits the sclerotomal pattern. Some cases do not fit it, however, suggesting alternative mechanisms or earlier mutations affecting multiple lineages.

Histopathology. Affected bone is dense, mature, well-organised lamellar bone, not woven, with normal osteons (Haversian systems preserved), thickened trabeculae and layers of periosteal new bone on the cortical surface. Adjacent soft tissues show dense fibrosis. Two negatives matter for the differential:

• No inflammatory infiltrate - distinguishes it from chronic osteomyelitis
• No nuclear atypia - distinguishes it from malignancy

View larger

View larger

The spectrum. Presentation is highly variable, from incidental discovery to severe disability, and many cases are discovered incidentally on imaging. Onset is insidious and the course slowly progressive over years. When symptoms bring the patient, they are these:

• Pain (50-80%) - dull and aching, often worse with activity
• Stiffness (60-80%) - joint contractures and reduced range of motion
• Deformity (40-60%) - limb length discrepancy or angular deformity
• Skin changes (20-40%) - scleroderma-like hardening over affected areas
• Limb swelling (30%) - from bone enlargement and soft-tissue involvement

Pain. Deep, aching bone pain over the affected segment, often worse with activity and sometimes present at night. It worsens slowly over years.

Contractures. They affect the joints adjacent to affected bones and arise from soft-tissue fibrosis and capsular involvement. Common sites are the knee, elbow, ankle and fingers. Severity ranges from mild limitation to a severe fixed contracture, and it gradually worsens over time.

View larger

View larger

Look. The limb may be asymmetric, shorter or angulated. The skin may be thickened and indurated with a scleroderma-like appearance, bone enlargement is visible where the bone is superficial, and muscle wastes from disuse or direct involvement.

Feel. Hard, irregular bone masses lie along the cortical surface and are non-tender or mildly tender. The skin may feel indurated and bound down, with reduced soft-tissue mobility over affected areas.

Move. Adjacent joints are contracted, fixed flexion deformities are common, and stretching produces end-range pain.

By age. The presentation shifts with age:

• Childhood (under 10 years) - limb length discrepancy, angular deformity and delayed motor milestones; it may be mistaken for a developmental condition
• Adolescence and young adulthood - pain with increasing activity, stiffness affecting sport and activities, and cosmetic concerns; this is the peak time for diagnosis
• Adulthood - progressive pain and stiffness, occupational limitations and osteoarthritis in affected joints; the patient may have been symptomatic for decades before diagnosis

Across ages, examination should relate the visible deformity and contracture to the same segmental distribution seen on imaging.

Sclerosing DysplasiasMalignant MimicsBenign Conditions

Pattern and symmetry separate the sclerosing dysplasias. Osteopoikilosis (spotted bones) consists of multiple small, round, well-defined sclerotic foci clustered near joints, completely different from the flowing, linear dripping wax of melorheostosis. Osteopoikilosis and osteopathia striata are bilateral and symmetric, where melorheostosis follows one sclerotome on one side.

Melorheostosis

Radiographic Pattern

Dripping candle wax

Distribution

Sclerotomal, unilateral

Key Distinguishing Feature

Flowing cortical hyperostosis along one cortex

Osteopoikilosis

Radiographic Pattern

Multiple round foci (spotted bones)

Distribution

Bilateral, symmetric

Key Distinguishing Feature

Round/oval sclerotic foci near joints

Osteopathia striata

Radiographic Pattern

Linear striations

Distribution

Bilateral, symmetric

Key Distinguishing Feature

Longitudinal dense lines in metaphyses

Progressive diaphyseal dysplasia

Radiographic Pattern

Fusiform cortical thickening

Distribution

Bilateral, symmetric, diaphyseal

Key Distinguishing Feature

Camurati-Engelmann, inherited, systemic symptoms

Condition	Radiographic Pattern	Distribution	Key Distinguishing Feature
Melorheostosis	Dripping candle wax	Sclerotomal, unilateral	Flowing cortical hyperostosis along one cortex
Osteopoikilosis	Multiple round foci (spotted bones)	Bilateral, symmetric	Round/oval sclerotic foci near joints
Osteopathia striata	Linear striations	Bilateral, symmetric	Longitudinal dense lines in metaphyses
Progressive diaphyseal dysplasia	Fusiform cortical thickening	Bilateral, symmetric, diaphyseal	Camurati-Engelmann, inherited, systemic symptoms

Mixed sclerosing bone dysplasia. Some patients show features of more than one sclerosing dysplasia, melorheostosis with osteopoikilosis or osteopathia striata with osteopoikilosis. The overlap is not coincidence: these dysplasias share disturbances in the same bone-forming signalling pathways, which suggests a common pathogenetic mechanism.

Parosteal osteosarcoma

Key Features

Low-grade surface osteosarcoma

Imaging Clues

Lobulated, encircles cortex, radiolucent cleft

Definitive Diagnosis

Biopsy shows malignant osteoid production

Osteoblastic metastases

Key Features

History of primary cancer

Imaging Clues

Multiple lesions, axial predominance

Definitive Diagnosis

Clinical history, biopsy

Sclerosing osteosarcoma

Key Features

Aggressive bone tumour

Imaging Clues

Periosteal reaction, soft tissue mass

Definitive Diagnosis

Biopsy shows high-grade malignancy

Condition	Key Features	Imaging Clues	Definitive Diagnosis
Parosteal osteosarcoma	Low-grade surface osteosarcoma	Lobulated, encircles cortex, radiolucent cleft	Biopsy shows malignant osteoid production
Osteoblastic metastases	History of primary cancer	Multiple lesions, axial predominance	Clinical history, biopsy
Sclerosing osteosarcoma	Aggressive bone tumour	Periosteal reaction, soft tissue mass	Biopsy shows high-grade malignancy

Parosteal Osteosarcoma Differentiation

Parosteal osteosarcoma is the most important malignant mimic. It is lobulated and tends to encircle the bone, where melorheostosis flows along one cortex, and it often has a radiolucent cleft between tumour and cortex initially. It is a discrete mass, not a flowing linear pattern, and a clinical history of slow progression over decades favours melorheostosis. When in doubt, biopsy is mandatory.

View larger

Myositis ossificans

Key Features

Post-traumatic heterotopic ossification

Differentiation from Melorheostosis

History of trauma, zonal phenomenon, matures peripherally

Chronic osteomyelitis

Key Features

Sclerotic bone with sequestrum

Differentiation from Melorheostosis

History of infection, cloaca, involucrum, inflammatory markers

Fibrous dysplasia

Key Features

Ground-glass matrix

Differentiation from Melorheostosis

Central lesion, not cortical, different matrix pattern

Caffey disease

Key Features

Infantile cortical hyperostosis

Differentiation from Melorheostosis

Infants only, mandible involvement, fever, self-limiting

Condition	Key Features	Differentiation from Melorheostosis
Myositis ossificans	Post-traumatic heterotopic ossification	History of trauma, zonal phenomenon, matures peripherally
Chronic osteomyelitis	Sclerotic bone with sequestrum	History of infection, cloaca, involucrum, inflammatory markers
Fibrous dysplasia	Ground-glass matrix	Central lesion, not cortical, different matrix pattern
Caffey disease	Infantile cortical hyperostosis	Infants only, mandible involvement, fever, self-limiting

View larger

When to biopsy. The diagnosis is usually radiographic, and biopsy is kept for the cases that leave doubt:

• Diagnosis uncertain despite classic imaging
• Atypical features suggesting malignancy
• Rapid progression, which is unusual for melorheostosis
• A soft-tissue mass concerning for parosteal osteosarcoma
• A patient under 5 years, which is very rare for melorheostosis; consider other causes

Conservative management is the mainstay. Most patients can be managed with analgesics, physiotherapy and supportive measures. Surgery has unpredictable results with high recurrence rates, and it is reserved for severe contractures or deformity causing functional impairment after conservative treatment has failed.

ConservativeSurgicalComplications

Analgesia. NSAIDs are the first-line analgesics, but the response is variable and relief often partial:

• NSAIDs - first line
• Paracetamol - adjunct for mild pain
• Neuropathic agents - gabapentin or pregabalin if there is nerve involvement
• Opioids - reserved for severe, refractory pain
• Local measures - heat, ice, TENS

Physiotherapy. The goals are to maintain range of motion and prevent contracture progression. Regular stretching of the affected joints and strengthening to maintain muscle function are the core; hydrotherapy may help pain and mobility, and among orthotics, splints maintain position and AFOs manage drop foot.

Bisphosphonates. They inhibit osteoclast activity and reduce bone turnover. Melorheostosis is primarily an osteoblastic condition and their effect on bone formation is limited, and the excess osteoid of the Kang work is the reason merely restraining resorption is only partly helpful. Even so, they may reduce pain in a subset of patients, so a trial is reasonable for the symptomatic patient:

• Alendronate 70mg weekly, or
• Zoledronic acid 5mg IV annually
• Trial for 6-12 months to assess response

Limited Evidence for Bisphosphonates

Evidence for bisphosphonate efficacy in melorheostosis is limited to case reports and small case series. Response is variable, with some patients experiencing significant pain relief and others showing no benefit. A therapeutic trial is reasonable but patients should be counselled about uncertain efficacy.

MEK inhibitors. Because the activating mutation makes MEK1 signal constitutively to ERK, a MEK inhibitor (for example trametinib or selumetinib) blocks the mutated kinase directly. That makes it the rational pathway-directed therapy, from a drug class already established in other RAS-MAPK RASopathies (selumetinib is approved for NF1 plexiform neurofibromas). It remains investigational: use in melorheostosis is off-label and unproven, so it is not standard care and conservative management stays first-line.

Other drugs. Nifedipine, a calcium channel blocker, has been reported to reduce pain in isolated cases. Denosumab, a RANKL inhibitor, has a theoretical benefit and case reports only.

Indications. Surgery is kept for severe contractures causing functional impairment, angular deformity requiring correction, limb length discrepancy requiring equalisation, nerve compression syndromes and the removal of symptomatic osteophytes. What each operation offers, and what it risks, is set out below.

Surgery Has Limited Role

Surgical treatment of melorheostosis has high recurrence rates and unpredictable outcomes. Patients must be counselled about the high likelihood of disease recurrence and potential for postoperative stiffness.

Severe fixed flexion contracture

Procedure

Soft tissue release, capsulotomy

Expected Outcome

Variable improvement in ROM

Complication Risk

High - recurrent contracture common

Angular deformity

Procedure

Corrective osteotomy

Expected Outcome

Deformity correction achievable

Complication Risk

Moderate - delayed union, recurrence

Limb length discrepancy

Procedure

Epiphysiodesis or lengthening

Expected Outcome

Length equalisation possible

Complication Risk

Standard limb length surgery risks

Nerve compression

Procedure

Decompression, neurolysis

Expected Outcome

Variable symptom relief

Complication Risk

Recurrence of compression possible

Indication	Procedure	Expected Outcome	Complication Risk
Severe fixed flexion contracture	Soft tissue release, capsulotomy	Variable improvement in ROM	High - recurrent contracture common
Angular deformity	Corrective osteotomy	Deformity correction achievable	Moderate - delayed union, recurrence
Limb length discrepancy	Epiphysiodesis or lengthening	Length equalisation possible	Standard limb length surgery risks
Nerve compression	Decompression, neurolysis	Variable symptom relief	Recurrence of compression possible

Soft-tissue release. Identify the contracted structures, capsule, ligaments and fascia, and release every contracted element completely; an extensive release is often required. Assess range of motion on the table and start therapy immediately after surgery. Recurrence runs at 50% or more.

Corrective osteotomy. Standard osteotomy principles apply, but the sclerotic bone is difficult to cut and healing may be delayed, so bone graft augmentation may be needed. Internal fixation is achievable but challenging, and the disease may recur at the osteotomy site.

View larger

View larger

Bone excision. Removal of symptomatic bony prominences is worth considering for isolated, accessible lesions; complete excision of the affected segment is rarely possible. Recurrence of sclerotic bone is taught as common, and the patient should be warned of it, although Wordsworth and Chan's review found bone regrowth after surgery uncommon and recurrent soft-tissue contracture the major surgical problem.

View larger

View larger

View larger

View larger

View larger

After surgery. Intensive physiotherapy is essential to maintain the gains, continuous passive motion may help prevent recurrent stiffness, and night splints maintain position. Follow the patient closely for recurrence, and counsel them about the likely need for repeat procedures.

Recurrence. After soft-tissue release it may occur within months, and the same tissues re-contract. Intensive early mobilisation is the prevention; repeat release with aggressive physiotherapy is the treatment.

Stiffness. The paradox of this disease is that surgery for stiffness may cause more of it, through tissue fibrosis and scarring, and range of motion is often worse than before the operation. Early aggressive mobilisation is the prevention, and CPM may help maintain the gains.

Wounds. Skin involvement may impair healing: sclerodermatous skin is fragile and compromised tissue carries a higher infection risk. A plastic surgery consultation may be needed, and staged procedures are worth considering for extensive surgery.

Nerves and vessels. Fibrotic tissue encases the neurovascular structures, so dissection is difficult and hazardous, and the risk of injury is higher than in standard surgery. Preoperative imaging is essential, and adherent nerves may need neurolysis.

Disease progression. Surgery does not halt the disease. New areas of involvement may develop and adjacent joints may become affected, so long-term outcome depends on the extent of disease, not on the operation, and realistic expectations are essential in counselling.

Global Epidemiology

• Incidence: approximately 1 per 1,000,000 — among the rarest sclerosing bone dysplasias; no geographic clustering reported
• Distribution: lower-limb predominant (about two-thirds), polyostotic more common than monostotic in cohort series; female predominance (up to 4:1) in the Mayo cohort, though earlier series report an equal sex ratio
• Age: any age; most present as young adults, with diagnostic delay of years to decades being typical worldwide

Reference Sources Instead of Guidelines

Practice Variation by Resource Setting

Pragmatic Global Principles

• Diagnosis is usually radiographic; reserve biopsy for cases where parosteal osteosarcoma or another malignancy cannot be excluded
• Manage at, or in consultation with, a centre experienced in sclerosing bone dysplasias or musculoskeletal oncology
• Bisphosphonate and MEK-inhibitor use is off-label/investigational everywhere — counsel on uncertain efficacy and document informed consent
• Intensive, sustained physiotherapy is the single most important determinant of a durable result after any contracture surgery, irrespective of health system

1. Kang H, Jha S, Deng Z, et al. Somatic activating mutations in MAP2K1 cause melorheostosis. Nature Communications. 2018;9(1):1390. PMID: 29643386.
2. Freyschmidt J. Melorheostosis: a review of 23 cases. European Radiology. 2001;11(3):474-479. PMID: 11288855.
3. Hollick RJ, Black A, Reid D. Melorheostosis and its treatment with intravenous zoledronic acid. BMJ Case Reports. 2010;2010:bcr0420091757. PMID: 22479293.
4. Smith GC, Pingree MJ, Freeman LA, et al. Melorheostosis: a retrospective clinical analysis of 24 patients at the Mayo Clinic. PM&R. 2017;9(3):283-288. PMID: 27485676.
5. Wordsworth P, Chan M. Melorheostosis and osteopoikilosis: a review of clinical features and pathogenesis. Calcified Tissue International. 2019;104(5):530-543. PMID: 30989250.
6. De Ridder R, Boudin E, Zillikens MC, et al. A multi-omics approach expands the mutational spectrum of MAP2K1-related melorheostosis. Bone. 2020;137:115406. PMID: 32387835.
7. Hellemans J, Preobrazhenska O, Willaert A, et al. Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nature Genetics. 2004;36(11):1213-1218. PMID: 15489854.